Project Grant R21CA297629
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$391K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Nebraska, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $514,196 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant, which runs from September 1, 2024 to April 2, 2027, will support research to investigate IGF2BP1 as a novel therapeutic target for Ewing sarcoma, the second most prevalent bone cancer among children. The project aims to validate IGF2BP1 as an Ewing sarcoma dependency, determine the molecular...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $523,292 to the Dana-Farber Cancer Institute to investigate the molecular mechanisms by which the microhomology-mediated end-joining (MMEJ) DNA repair pathway is suppressed in Ewing sarcoma. The project aims to assess the function of the MMEJ pathway in Ewing sarcoma tumor tissue and explore exploiting this unique DNA repair defect for therapeutic benefit. The award period...
This National Cancer Institute (NCI) Project Grant award to Georgetown University, under the Cancer Biology Research program (CFDA 93.396), provides funding of $401,115 to develop a 3D bioengineered microfluidic platform (3D-BMP) to study the mechanisms of Ewing sarcoma bone metastasis. The project aims to utilize this 3D-BMP model to perform CRISPR screens and identify key genetic drivers of Ewing sarcoma's ability to metastasize to bone, a common occurrence that is associated with poor...
The National Cancer Institute (NCI) awarded a $1,335,041 project grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) on August 7, 2024. The grant aims to develop metabolic therapy and imaging techniques to improve outcomes and quality of life for patients with diffuse midline gliomas (DMGs), a type of devastating brain cancer in children. Specifically, the project will determine if combined inhibition of...
This $662,682 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at the University of California, San Diego (UCSD) to develop new combination therapies for treating gastrointestinal stromal tumors (GIST). The research aims to validate the use of voltage-gated potassium channels, specifically the KVβ1.1 protein, as a novel therapeutic target to eliminate both tyrosine kinase inhibitor-sensitive and resistant...
The National Cancer Institute (NCI) awarded a $477,576 Project Grant (CFDA 93.396 Cancer Biology Research) to George Washington University to advance the understanding of the novel function of the SIRT1 enzyme and its implications in cancer, particularly medulloblastoma. The 5-year project aims to define the molecular mechanisms by which SIRT1 regulates centrosomal and ciliary biogenesis, and explore the therapeutic potential of manipulating SIRT1 activity to repress the growth of sonic hedgehog...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $693,781 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research aimed at improving treatments for cancers with mutations in the IDH1 gene. The key goals of this 5-year project are to: Further understand how mutant IDH1 drives cancer growth and how IDH1 inhibitor drugs work to block cancer progression, including investigating...
This federal Project Grant award of $593,028.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research by the Beckman Research Institute of the City of Hope to investigate the role of IL-6/STAT3 signaling in CIC-DUX4 fusion sarcoma metastasis and immunosuppression. The goal is to define the critical role of IL-6/STAT3 signaling in tumor cell growth and metastasis, as well as in inducing tumor-associated macrophage recruitment and...
This federal Project Grant award of $216,972 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to understand and target vulnerabilities governing the G1/S transition and replication stress in small cell lung cancer (SCLC). The key objectives are to: 1) determine the mechanistic underpinnings of increased replication stress in SCLC, including the role of low LMNA levels and R-loops, and develop therapeutic approaches targeting...